Home Authors Posts by Winway Health Desk

Winway Health Desk

1469 POSTS 0 COMMENTS

Neurocrine’s 3rd Ingrezza flop in Tourette dashes hopes for sales expansion

Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing...

Blockchain becomes a ‘source of truth’ for biopharma

Whatever economic role bitcoin will ultimately play, the underlying technology that powers it and other cryptocurrencies — blockchain — has attracted a lot of...

Mylan, Biocon copy inches closer to challenging Sanofi’s long-suffering Lantus

Sanofi’s Lantus is already facing off against generic competition from Eli Lilly and Boehringer’s Basaglar, but now Mylan is adding to the pressure by...

Biogen pulls out of $1 billion partnership with AGTC after gene...

The failure of a gene therapy trial has led to the termination of a three-year-old partnership between one of the largest biotechnology companies and...

Whistleblower complaint against Sun Pharma confirmed by Indian regulators: report

Sun Pharma drew more unwanted attention this week when India’s stock regulators confirmed they are examining whistleblower allegations against the company. “We have received the complaint...

Florida startup raises $9M for on-demand pharmacist marketplace

Tampa, Florida-based startup Aspen RxHealth is launching out of stealth with $9 million in Series A funding to create an on-demand system to connect...

Warning, investors: Way too many drugs will be vying for market...

Biopharma knows this industry plague all too well: One company finds a new way to tackle a disease and a whole bunch of rivals...

University of Iowa Health Care picks Zingbox to monitor its IoT...

University of Iowa Health Care has deployed Zingbox’s IoT Guardian solution to protect and monitor its network of connected medical devices. Based in Mountain View,...

Government considers increasing power of pharmacists if a medicines shortage occurs

The government is considering introducing a measure to "provide an alternative" should there be a medicines shortage in event of a 'no-deal'...

AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial

AstraZeneca felt the blow last month when Mystic, a key trial examining its immuno-oncology drug Imfinzi in previously untreated lung cancer, failed. But now...
0FansLike
65,684FollowersFollow
20,394SubscribersSubscribe

EDITOR PICKS